Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LABP

Landos Biopharma Inc

May 10 • 04:00PM ET

22.33

Dollar change -0.03
Percentage change -0.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.99	Insider Own	9.92%	Shs Outstand	3.12M	Perf Week	0.43%
Market Cap	69.89M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	0.00%	Shs Float	2.82M	Perf Month	3.81%
Income	-24.80M	PEG	-	EPS next Q	-1.00	Inst Own	50.43%	Short Float	0.05%	Perf Quarter	331.08%
Sales	0.00M	P/S	-	EPS this Y	37.43%	Inst Trans	-32.01%	Short Ratio	0.06	Perf Half Y	439.37%
Book/sh	7.43	P/B	3.01	EPS next Y	23.06%	ROA	-61.17%	Short Interest	0.00M	Perf Year	697.50%
Cash/sh	9.28	P/C	2.41	EPS next 5Y	-	ROE	-70.67%	52W Range	2.50 - 22.84	Perf YTD	510.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.32%	ROI	-107.10%	52W High	-2.23%	Beta	0.13
Dividend TTM	-	Quick Ratio	4.43	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	793.20%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	4.43	EPS Y/Y TTM	42.89%	Oper. Margin	0.00%	RSI (14)	82.98	Volatility	0.93% 1.23%
Employees	19	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.33	Target Price	9.56
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-54.01%	Payout	-	Rel Volume	0.43	Prev Close	22.36
Sales Surprise	-	EPS Surprise	-8.20%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	25.19K	Price	22.33
SMA20	1.18%	SMA50	33.79%	SMA200	204.61%	Trades		Volume	10,749	Change	-0.13%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-22	Downgrade	Jefferies	Buy → Hold	$30 → $1.40
Nov-16-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$20 → $16
Oct-20-21	Initiated	Craig Hallum	Buy	$45
Oct-19-21	Initiated	H.C. Wainwright	Buy	$50
Mar-01-21	Initiated	SVB Leerink	Outperform	$20
Mar-01-21	Initiated	Raymond James	Outperform	$33
Mar-01-21	Initiated	JP Morgan	Neutral	$17
Mar-01-21	Initiated	Jefferies	Buy	$32

May-09-24 01:53PM	LABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024 (InvestorPlace)
Apr-30-24 08:38AM	AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript (Insider Monkey)
Mar-25-24 01:27PM	Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? (Benzinga) +173.31%
12:17PM	Why Is Landos Biopharma (LABP) Stock Up 168% Today? (InvestorPlace)
09:25AM	AbbVie grabs a wrench to add immunology-focused Landos Biopharma for $137.5M (FierceBiotech.com)
08:31AM	Loading…
08:31AM	AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases (PR Newswire)
08:05AM	AbbVie to buy immune drug developer Landos (BioPharma Dive)
Mar-21-24 01:52PM	LABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023 (InvestorPlace) +9.73%
08:00AM	Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Jan-08-24 08:00AM	Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis Organisation (GlobeNewswire)
Nov-21-23 08:00AM	Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis (GlobeNewswire) +7.42%
Nov-09-23 08:00AM	Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results (GlobeNewswire) -7.49%
Oct-23-23 08:00AM	Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting (GlobeNewswire)
Sep-19-23 08:00AM	Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress (GlobeNewswire)
Sep-14-23 08:00AM	Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells (GlobeNewswire)
08:00AM	Loading…
Aug-09-23 08:00AM	Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results (GlobeNewswire)
May-31-23 04:15PM	Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) -8.61%
May-30-23 04:15PM	Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. (GlobeNewswire)
May-25-23 04:05PM	Landos Biopharma Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -6.03%
May-12-23 08:50AM	UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results (GlobeNewswire)
08:00AM	Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results (GlobeNewswire)
Mar-23-23 08:00AM	Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire) -12.26%
Feb-28-23 05:00PM	Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos Founder (GlobeNewswire)
Jan-11-23 07:00AM	Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohns and Colitis Organization (GlobeNewswire) +11.75%
Jan-05-23 07:05AM	Landos Biopharma Provides Comprehensive Update on Clinical Development Plans (GlobeNewswire)
07:00AM	Landos Biopharma Announces $16.7 Million Private Placement Financing (GlobeNewswire)
Nov-10-22 08:00AM	Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update (GlobeNewswire) +17.39%
Oct-15-22 09:36AM	We're A Little Worried About Landos Biopharma's (NASDAQ:LABP) Cash Burn Rate (Simply Wall St.)
Sep-06-22 07:00AM	Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer (GlobeNewswire)
Aug-12-22 06:37PM	Raymond James Is Bearish On This Inflammatory Bowel Disease Player On Upcoming 'Pipeline Reset' (Benzinga)
08:30AM	Loading…
Aug-11-22 08:30AM	Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update (GlobeNewswire) -12.20%
Aug-03-22 08:00AM	Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial (GlobeNewswire) +17.03%
Jun-21-22 08:00AM	Landos Names Gregory Oakes President and Chief Executive Officer (GlobeNewswire)
May-13-22 08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 04:05PM	Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update (GlobeNewswire) +5.72%
May-11-22 07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks) -8.11%
May-08-22 09:00AM	We're Keeping An Eye On Landos Biopharma's (NASDAQ:LABP) Cash Burn Rate (Simply Wall St.)
Mar-24-22 04:45PM	Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update (GlobeNewswire)
Mar-10-22 08:00AM	Landos Biopharma Appoints Roger Adsett to its Board of Directors (GlobeNewswire) -5.88%
Feb-04-22 07:23AM	What Percentage Of Landos Biopharma, Inc. (NASDAQ:LABP) Shares Do Insiders Own? (Simply Wall St.) -8.42%
Nov-17-21 08:33AM	Here's Why We're Not At All Concerned With Landos Biopharma's (NASDAQ:LABP) Cash Burn Situation (Simply Wall St.)
Nov-15-21 07:30AM	Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.48%
Nov-11-21 04:05PM	Landos Biopharma to Host Corporate Update Call (GlobeNewswire)
Nov-10-21 08:32AM	Should You Buy Landos Biopharma (LABP) Ahead of Earnings? (Zacks)
Nov-08-21 08:10AM	Landos Biopharma Announces Leadership Transition (GlobeNewswire)
Nov-02-21 08:28AM	Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis (GlobeNewswire)
Oct-28-21 07:00AM	Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus (GlobeNewswire)
Oct-15-21 08:49AM	10 Best Biotech Stocks to Buy According to Joseph Edelmans Perceptive Advisors (Insider Monkey)
Oct-11-21 07:00AM	Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Oct-06-21 07:00AM	Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancors Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism (GlobeNewswire)
Sep-27-21 07:00AM	Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual) (GlobeNewswire)
Sep-20-21 07:00AM	Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohns Disease with the Icahn School of Medicine at Mount Sinai (GlobeNewswire)
Sep-15-21 07:00AM	Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021 (GlobeNewswire) +11.21%
Sep-01-21 07:00AM	Landos Biopharma to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-26-21 07:00AM	Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine (GlobeNewswire)
Aug-19-21 03:03PM	Here's What Landos Biopharma, Inc.'s (NASDAQ:LABP) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Aug-05-21 07:00AM	Landos Biopharma to Participate in Upcoming Investor Events (GlobeNewswire) +8.89%
Jul-22-21 07:00AM	Landos Biopharmas Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021 (GlobeNewswire)
Jun-14-21 05:08PM	Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference (GlobeNewswire)
07:00AM	Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients (GlobeNewswire)
May-25-21 07:00AM	Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-19-21 07:00AM	Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors (GlobeNewswire)
May-17-21 09:29AM	Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China (Benzinga)
07:15AM	Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets (GlobeNewswire)
May-06-21 04:01PM	Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohns Disease (GlobeNewswire)
May-04-21 08:51AM	Is Landos Biopharma (NASDAQ:LABP) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-29-21 07:00AM	Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis (GlobeNewswire)
Apr-26-21 11:56AM	Raymond James: These 3 Stocks Have Over 100% Upside on the Horizon (TipRanks) +16.21%
07:00AM	Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting (GlobeNewswire)
Apr-13-21 07:00AM	Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors (GlobeNewswire)
Apr-06-21 09:53AM	Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation (Benzinga) +7.99%
07:00AM	Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis (GlobeNewswire)
Mar-04-21 07:00AM	Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers (GlobeNewswire) -15.35%
Feb-26-21 06:26PM	Bausch Health and Landos Biopharma See Activist Action (Barrons.com)
Feb-23-21 04:00PM	Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference (GlobeNewswire) -6.46%
Feb-05-21 05:26PM	The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market (Barrons.com) -7.92%
Feb-04-21 05:56PM	A Busy Day for Biotech IPOs (Barrons.com)
Feb-03-21 08:13PM	Landos Biopharma Announces Pricing of Initial Public Offering (GlobeNewswire)

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LABP

Landos Biopharma Inc

Upgrade your FINVIZ experience